AOD-9604: Dosage & Administration
Part of the AOD-9604 Complete Guide
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
AOD-9604 Dosage Protocols
AOD-9604 dosing in research and clinical settings:
| Route | Dose | Timing | Notes |
|---|---|---|---|
| Subcutaneous | 250–500 mcg daily | Morning, fasted | Most common research protocol |
| Oral | 1 mg daily | Before meals | Used in clinical trials |
The 250 mcg dose is commonly used as a starting point, with 500 mcg being the upper range in most published protocols.
Why Fasted Administration?
AOD-9604 is typically administered in a fasted state because insulin — which rises after eating — directly inhibits hormone-sensitive lipase and lipolysis, counteracting AOD-9604's primary mechanism.
- At least 2 hours after the last meal
- Wait 30–60 minutes after injection before eating
- Morning administration upon waking is most practical
Reconstitution
AOD-9604 is supplied as lyophilized powder, typically in 2mg or 5mg vials. Use the peptide calculator for precise volumes. See the reconstitution guide for step-by-step preparation.
Cycle Length
Research protocols typically run 8–12 weeks. Clinical trials used 12-week treatment periods. No loading dose or taper is required.